We found that K102-Env was present in 34.00% of patients with PDAC, 39% of patients with HCC, and 28.0% of patients with NSCLC, whereas only 5.0% of healthy individuals had marginally increased HERV-K102. This evidence concerns the gene ERVW-1 and hepatocellular carcinoma.